Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (July 2021)
38 slides from Innate Pharma Sa Class A's investor presentation, July 2021
Slide 1: Company Overview
Company Overview July 2021 PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: A Leading Company in the Field of Innate Immunity
A Leading Company in the Field of Innate Immunity • Global, clinical-stage oncology-focused MARSEILLE FRANCE biotech company. ROCKVILLE MARYLAND • Scientific excellence in the field of innate immunity with expertise in natural killer cell biology and antibody engineering. • Focused pipeline of antib
Slide 4: Scientific Innovation Drives Our Strategy
Scientific Innovation Drives Our Strategy We aim to harness our scientific know-how in innate immunity and antibody engineering to develop oncology products that improve the lives of patients Drive near-term Advance our Build a value with innovative R&D sustainable Lacutamab pipeline business 4
Slide 5: Strong Science + Strong Partnerships = Robust Pipeline
Strong Science + Strong Partnerships = Robust Pipeline Validated Strong Track Robust Science Record of Pipeline in high-impact Collaborations with innovative publications pre-clinical and with industry and clinical assets academia 5
Slide 6: Innate's Approach: Harnessing Innate Immunity in Cancer
Innate’s Approach: Harnessing Innate Immunity in Cancer Choosing the right targets to leverage the body’s immune response Priming and activation (APCs and T cells) Engage NK cells 1 towards tumor Cancer antigen presentation (DCs) Lacutamab (KIR3DL2) Lymph node Trafficking of ANKETTM (NKp46) T cells
Slide 7: Our Pipeline
Our Pipeline Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Partner Sézary Syndrome PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) – Lacutamab KIR3DL2 (IPH4102) Mycosis Fungoides PHASE 2 – Squamous Cell Carcinoma of the Head and PHASE 3 Neck Monalizumab NKG2A Solid Tumors (including
Slide 8: Driving Our Proprietary Portfolio
Driving Our Proprietary Portfolio
Slide 9: Lacutamab: Lead Proprietary Asset
LACUTAMAB Lacutamab: Lead Proprietary Asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody lacutamab • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) KIR3DL2 • Compelling Phase 1 data in Sézary syndrome (SS), published in Lancet Oncolog
Slide 10: Development Informed by Target Expression
LACUTAMAB Development Informed by Target Expression KIR3DL2 EXPRESSION INCIDENCE Major markets (US, EU5, Japan), 2025 SEZARY SYNDROME • >90% of patients express target* ~80–200 patients1 • All tissues involved (skin, blood and lymph nodes) MYCOSIS FUNGOIDES 2,200–4,000 patients1 • ~50% of patients e
Slide 11: Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas
LACUTAMAB Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas Sezary Cutaneous Syndrome T-Cell Lymphoma Fast to market approach (CTCL) Niche indication with high unmet need Mycosis Fungoides Expand potential beyond SS Explore impact of KIR3DL2 expression on clinical outcome Periph
Slide 12: Compelling Phase 1 Results
LACUTAMAB Compelling Phase 1 Results FDA Fast Track Designation granted based on these results Sézary Syndrome Subgroup (n=35) Total 44 patients with CTCL ≥ 2 lines of therapy Best change in mSWAT as compared to baseline Best Global Response • 25 (incl. 20 SS) in dose escalation (intra-patient dose
Slide 13: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~90) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort #1 Cohort #2 Cohort #3 All comers, SS, must include KIR3DL2 expressing
Slide 14: Encouraging Preliminary Results in MF Cohort of TELLOMAK Trial
LACUTAMAB Encouraging Preliminary Results in MF Cohort of TELLOMAK Trial Overall response rate of ~35% in advanced patient population with no current standard of care 4 confirmed (1CR, 3PR) & 2 not yet confirmed (uPR) global responses** 9 / 17 patients still ongoing therapy * reported after DCO date
Slide 15: Promising Skin Responses Seen in Patients Receiving More Than 2 Lines of Therapy
LACUTAMAB Promising Skin Responses Seen in Patients Receiving More Than 2 Lines of Therapy Cohort 2 – KIR3DL2 ≥ 1% Cohort 3 – KIR3DL2 < 1% Skin (N = 17) Skin (N = 19) Involved at Involved at Responses Responses Compartment baseline Compartment baseline (cohort 2) (cohort 3) (cohort 2) (cohort 3) Ski
Slide 16: Initiating Data-Driven Strategy in PTCL
LACUTAMAB Initiating Data-Driven Strategy in PTCL N O W N E X T S T E P S RELAPSED SETTING 03 FRONTLINE Highest unmet medical need; Driven by data in the relapsed two-pronged approach: setting to advance into earlier lines 02 • Monotherapy (Phase 1b study in mid- 2021) • Combination with CHOP • Comb
Slide 17: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients ~18,000 p
Slide 18: Next-Generation Assets: NK Cell Engagers
Next-Generation Assets: NK Cell Engagers
Slide 19: NK Cells Offer Unique Cancer-Fighting Abilities
NK CELL ENGAGERS NK Cells Offer Unique Cancer-Fighting Abilities NK SPECIFICITY • NK cells are not expected to produce a cytokine storm NK cells in • NKp46 is the most specific activating receptor of NK cells periphery N K p 4 6 E X P R E S S I O N S TA B I L I T Y NKp46 • Unlike many other activati
Slide 20: ANKET: Innate's Proprietary NK Cell Engager Platform
NK CELL ENGAGERS ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for-purpose technology Provides proliferation and activation signals that is
Slide 21: First ANKET Drug Candidate: IPH6101/SAR443579
NK CELL ENGAGERS First ANKET™ Drug Candidate: IPH6101/ SAR443579 Research collaboration with Sanofi Innate’s lead ANKET Uses Innate’s Has triggered €7M asset selected by Sanofi proprietary multi-specific milestone payment to as drug candidate for antibody format Innate to date development • Companie
Slide 22: Different Receptors have Different Effects on NK cells
NK CELL ENGAGERS Different Receptors have Different Effects on NK cells NKG2D NKp46 CD16 IL-2Rb IL-2Rg DAP10 CD3ζ, FcRγ # • NK cell activation + • NK cell activation +++ • Proliferation +++ • cytotoxicity • cytotoxicity • cytokines and chemokines Adapted from Lanier, Nature Immunol 2008; Vivier et a
Slide 23: Optimal Efficacy Requires All Arms in a Single Tetra-specific ANKET
NK CELL ENGAGERS Optimal Efficacy Requires All Arms in a Single Tetra-specific ANKET™ aTAg IL2v aTAg IL2v + Vehicle Vehicle aNKp46 Fc aNKp46 Fc Fc null 1500 1500 1500 Tumor volume (mm3) Tumor volume (mm3) Tumor volume (mm3) 1000 1000 1000 500 500 500 0 0 0 0 10 20 30 40 0 10 20 30 40 0 10 20 30 40 D
Slide 24: Superiority of Tetra-specific ANKET in a Preclinical Model of Disseminated Tumors
NK CELL ENGAGERS Superiority of Tetra-specific ANKET™ in a Preclinical Model of Disseminated Tumors aTAg IL2v aNKp46 Fc Vehicle Obinutuzumab* * ADCC-enhanced mAb 24
Slide 25: Building a Sustainable Business
Building a Sustainable Business
Slide 26: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN Promotes Anti-tumor Immunity by 2H20: Phase 3 Start Triggered First of Two Unleashing Both T and NK Cells $50M
Slide 27: Avdoralimab: Exploring in Inflammation
AVDORALIMAB Avdoralimab: Exploring in Inflammation Will stop trials in COVID-19 Inflammatory Diseases COVID-19 Severe Pneumonia • Targeting C5a/C5aR1 has been demonstrated • FORCE Phase 2 trial did not meet its primary scientifically and through positive clinical trials in endpoints in all three coh
Slide 28: Catalysts and Summary
(fo) Catalysts and Summary &S innate pharma
Slide 29: Key Catalysts Over the Next 24 Months
Key Catalysts Over the Next 24 Months 2 0 2 1 PRECLINICAL LACUTAMAB MONALIZUMAB • Update on NKCE platform • Preliminary Phase 2 MF data • Preliminary data on the development (FOCIS (ICML Lugano meeting) combination of monalizumab, meeting) • Start of PTCL monotherapy cetuximab and durvalumab in and
Slide 30: Summary: Driving Value Across our Business
Summary: Driving Value Across our Business Driving near-term Progressing an Building a sustainable value with Lacutamab innovative and robust business R&D portfolio • Initiate monotherapy and • Monalizumab: Phase 3 trial • Leverage proprietary NK cell- combination PTCL studies in 2021 ongoing, $50M
Slide 31: Thank You
THANK YOU www.innate-pharma.com PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.
Slide 32: Appendix
Appendix & innate pharma
Slide 33: Full Year 2020 Financial Highlights
Full Year 2020 Financial Highlights In thousands of euros, except for data per share December 31, 2020 December 31, 2019 Revenue and other income 70,451 85,814 Research and development (58,613) (78,844) Selling, general and administrative (31,246) (25,803) Total operating expenses (89,859) (104,647)
Slide 34: Putting Lacutamab Phase 1 Data into Clinical Context
LACUTAMAB Putting Lacutamab Phase 1 Data into Clinical Context Recent results in MF/Sézary patients Mogamulizumab Vorinostat Patient population Patients who received at least one prior systemic therapy Response rate MF/SS: 28% MF/SS: 5% MF: 21% MF: 7% SS: 37% Sézary: 2% Median progression-free survi
Slide 35: Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial
MONALIZUMAB Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial Cohort 2 post platinum and post anti-PD-(L)1 (n=40) Best Change of Tumor Size From Baseline • Population with high medical need • R/M SCCHN post platinum and post anti-PD-(L)1 where no treatment options are currently approved glob
Slide 36: IPH5201 (Anti-CD39) and IPH5301 (Anti-CD73)
IPH5201 & IPH5301 IPH5201* (Anti-CD39) and IPH5301 (Anti-CD73) Targeting immunosuppressive tumor microenvironment • CD39 and CD73 are enzymes expressed on different cells in the TME • Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • IPH5201: ongoing Pha
Slide 37: IPH5201: Preclinical Data
IPH5201 IPH5201*: Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC-inducing antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice Sources: Perrot et al., Cell Reports 2019 *2018 collab
Slide 38: IPH5301: Preclinical Data
IPH5301 IPH5301: Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP-suppression assay, than the most advanced clinical candidates CD4+ T cells + CD8+ T+ cells C D 4 T c e lls C D 8 T c e lls c o n tr o l) * * * r a te 1 0 0 * * * * 1 0 0 * * * 8 0 8 0 P r